Cytomegalovirus (CMV) Infections - Pipeline Assessment

and Market Forecasts to 2019

On 18thNovember 2014

Summary
The industry analysis specialist, has released its new report, Cytomegalovirus (CMV) Infections
- Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of
information and analysis on the global Cytomegalovirus (CMV) Infections Therapeutics market.
The report identifies the key trends shaping and driving the global Cytomegalovirus (CMV)
Infections Therapeutics market. The report also provides insights on the prevalent competitive
landscape and the emerging players expected to significantly alter the market positioning of the
current market leaders. Most importantly, the report provides valuable insights on the pipeline
products within the global Cytomegalovirus (CMV) Infections Therapeutics sector. This report is
built using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by Our team of industry experts.

You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-cytomegalovirus-cmv-infections-pipeline-assessment-and-marketforecasts-135247

Scope
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan)
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Cytomegalovirus (CMV) Infections Therapeutics market revenues data from 2006 to 2011,
forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being
developed and emerging trends by seven key markets. Pipeline candidates fall under major
therapeutic classes.
- Analysis of the current and future competition in the seven key countries Cytomegalovirus
(CMV) Infections Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet
needs and the implications for the Cytomegalovirus (CMV) Infections Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Cytomegalovirus (CMV)
Infections Therapeutics market.

Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline
products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
Cytomegalovirus (CMV) Infections Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments and companies likely to impact the global Cytomegalovirus (CMV) Infections
Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments and strategic
partnerships.
- Whats the next big thing in the global Cytomegalovirus (CMV) Infections Therapeutics market
landscape? Identify, understand and capitalize.

Email ID- contact@jsbmarketresearch.com

Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Other industries we cover:

Advertising and Media

Automotive and Parts
Consumer Goods
Healthcare and Medical
Finance and Banking
Food and Beverages
Travel and Tourism
Textiles and Clothing
SWOT Analysis

Discounts on Market Research Reports till 31st December, 2014

For more inquiries, contact at +91 - 998 729 5242 /
contact@jsbmarketresearch.com

Table of Content
2 Introduction
2.1 Catalyst
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Risk Factors
3.2 Epidemiology
3.2.1 CMV Prevalence in General Population
3.2.2 CMV Prevalence in At-Risk Populations
3.3 Symptoms
3.4 Diagnosis and Referral
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

3.4.1 CMV DNA PCR

3.4.2 Conventional viral cultures of tissue biopsy or bodily fluids
3.4.3 Shell vial culture
3.4.4 CMV serology
3.4.5 Histopathologic exam with in-situ hybridization
3.4.6 Retinal examination using an indirect ophthalmoscope
3.4.7 PP65 antigenemia test
3.4.8 Referral
3.5 Treatment Guidelines
3.6 Disease Management
4 Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products
4.3.1 Ganciclovir sodium
4.3.2 Valcyte (valganciclovir)
4.3.3 CMV-IGIV
4.3.4 Cidofovir
4.3.5 Foscarnet
4.3.6 Summary of Marketed Drugs
5 Opportunity and Unmet Need
5.1 Overview
5.2 Unmet Needs
5.2.1 Unmet Need: Safety
5.2.2 Unmet Need: Efficacy
5.2.3 Unmet Need: Prophylactic Vaccine
5.2.4 Unmet Need: Therapeutic Vaccine
5.2.5 Unmet Need: Patient Compliance
5.2.6 Unmet Need: Patient Awareness
5.2.7 Unmet Need: Physician Education
5.2.8 Unmet Need: Early Diagnosis of CMV in Pregnant Women and Transplant Patients
5.2.9 Unmet Need: Drug Resistance with Currently Available Antiviral Drugs
5.3 Opportunities
5.3.1 Opportunity: Vaccine Development Remains a Major Opportunity
5.3.2 Opportunity: Addressing Patient Compliance for Long-Term Therapy
5.3.3 Opportunity: Generating Physician and Patient Awareness
6 Pipeline Assessment
6.1 Overview
6.2 Strategic Pipeline Assessment
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

6.3 Pipeline Analysis by Phase of Development

6.3.1 Phase III Clinical Pipeline
6.3.2 Phase II Clinical Pipeline
6.3.3 Phase I Pipeline
6.3.4 Pre-clinical Pipeline
6.3.5 Discovery Pipeline
6.4 Pipeline by Mechanism of Action
6.5 Technology Trends Analytical Framework
6.6 Most Promising Drugs in Clinical Development
6.7 Most Promising Drug Profiles
6.7.1 TransVax
6.7.2 AIC246
6.7.3 Maribavir
6.7.4 CMX001
7 Clinical Trial Mapping
7.1 Clinical Trials by Region/Country (US, 5EU and Japan)
7.2 Clinical Trials by Phase
7.3 Clinical Trials by Trial Status
7.4 Clinical Trials by Prominent Sponsors
8 Current and Future Players
8.1 Trends in Corporate Strategy
8.2 Company Profiles
8.2.1 F. Hoffmann-La Roche (Roche)
8.2.2 Vical
8.2.3 AiCuris
8.2.4 ViroPharma
8.2.5 Chimerix
9 Licensing and Partnership Deals
9.1 Overview
9.2 Key Deals and Alliances in the Past 18 Months
10 Market Outlook
10.1 Seven Major Markets Overview
10.2 Regional Analysis
10.2.1 US
10.2.2 France
10.2.3 Germany
10.2.4 Italy
10.2.5 Spain
10.2.6 UK
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

10.2.7 Japan
10.3 Key Events
10.4 Drivers and Barriers
10.4.1 Drivers for the CMV Infections Market
10.4.2 Barriers for the CMV Infections Market
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Forecasting Methodology
11.3.4 Primary Research
11.3.5 Expert Panel Validation
11.4 Physicians and Specialists Included in this Study
11.5 About the Authors
11.5.1 Analysts
11.6 About Us
11.7 Contact Us
11.8 Disclaimer
List Of Tables
Table 1: Pre-transplant Serologic Status and Relative Risk
Table 2: Total Prevalent Cases of CMV Infection in the General Population in the Major Markets
(millions), 20112019
Table 3: Total Prevalent Cases in HSCT and SOT Recipients, Infants and HIV Patients with CMV
Infection in the Major Markets, 20112019
Table 4: Cytomegalovirus Assay Sensitivities and Predictive Values
Table 5: Treatment Guidelines for Cytomegalovirus
Table 6: Leading Treatments for Cytomegalovirus Infections, 2012
Table 7: Ganciclovir Sodium SWOT Analysis, 2012
Table 8: Product Profile Valcyte
Table 9: Trial Efficacy Details, Valcyte
Table 10: Valcyte SWOT Analysis, 2012
Table 11: CMV-IGIV SWOT Analysis, 2012
Table 12: Cidofovir SWOT Analysis, 2012
Table 13: Foscarnet SWOT Analysis, 2012
Table 14: Summary of Marketed Drugs, 2012
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Table 15: Overall Unmet Needs Current Level of Attainment (Prophylactic)

Table 16: Overall Unmet Needs Current Level of Attainment (Therapeutic)
Table 17: Cytomegalovirus Infections Market, Phase III Pipeline, 2012
Table 18: Cytomegalovirus Infections Market, Phase II Pipeline, 2012
Table 19: Cytomegalovirus Infections Market, Phase I Pipeline, 2012
Table 20: Cytomegalovirus Infections Market, Pre-clinical Pipeline, 2012
Table 21: Cytomegalovirus Infections Market, Discovery Pipeline, 2012
Table 22: Comparison of Mechanisms of Actions in Development for Cytomegalovirus Infection,
2012
Table 23: Cytomegalovirus Infections Market, Global, Most Promising Drugs in Clinical
Development, 2012
Table 24: Product Profile TransVax
Table 25: TransVax SWOT Analysis, 2012
Table 26: AIC246 SWOT Analysis, 2012
Table 27: Maribavir SWOT Analysis, 2012
Table 28: CMX001 SWOT Analysis, 2012
Table 29: Cytomegalovirus Infections, Global, Clinical Trials by Phase, 2012
Table 30: Cytomegalovirus Infections, Global, Clinical Trials by Status of Development, 2012
Table 31: Cytomegalovirus Infections, Overall Sponsor Mix, 2012
Table 32: Key Companies in the Cytomegalovirus Infections Market, 2012
Table 33: Roches Cytomegalovirus Infections Portfolio Assessment, 2012
Table 34: Roches Cytomegalovirus Infections Market SWOT Analysis, 2012
Table 35: Vicals Cytomegalovirus Infections Portfolio Assessment, 2012
Table 36: Vicals Cytomegalovirus Infections Market SWOT Analysis, 2012
Table 37: AiCuris Cytomegalovirus Infections Portfolio Assessment, 2012
Table 38: AiCuris Cytomegalovirus Infections Market SWOT Analysis, 2012
Table 39: ViroPharmas Cytomegalovirus Infections Portfolio Assessment, 2012
Table 40: ViroPharmas Cytomegalovirus Infections Market SWOT Analysis, 2012
Table 41: Chimerixs Cytomegalovirus Infections Portfolio Assessment, 2012
Table 42: Chimerixs Cytomegalovirus Infections Market SWOT Analysis, 2012
Table 43: Strategic Deals and Alliances for Cytomegalovirus Infections, 2012
Table 44: Sales Forecasts ($m) for Cytomegalovirus Infections Market in the Seven Major
Markets, 20112019
Table 45: Sales Forecasts ($m) for Cytomegalovirus Infections in the United States, 20112019
Table 46: Sales Forecasts ($m) for Cytomegalovirus Infections in France, 20112019
Table 47: Sales Forecasts ($m) for Cytomegalovirus Infections in Germany, 20112019
Table 48: Sales Forecasts ($m) for Cytomegalovirus Infections in Italy, 20112019
Table 49: Sales Forecasts ($m) for Cytomegalovirus Infections in Spain, 20112019
Table 50: Sales Forecasts ($m) for Cytomegalovirus Infections in the UK, 20112019
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Table 51: Sales Forecasts ($m) for Cytomegalovirus Infections in Japan, 20112019
Table 52: Key Events Impacting Sales for Cytomegalovirus Infections, 2012
Table 53: Cytomegalovirus Infections Market Drivers and Barriers, 2012
Table 54: Key Launch Dates
Table 55: Key Patent Expiries
List Of Figures
Figure 1: Cytomegalovirus Infection in Organ Transplant Patients
Figure 2: Referral Pathway for Cytomegalovirus Infection
Figure 3: Strategic Competitor Assessment of Marketed Products in Cytomegalovirus Infections
(Prophylactic) Market, 2012
Figure 4: Strategic Competitor Assessment of Marketed Products in Cytomegalovirus Infections
(Therapeutics) Market, 2012
Figure 5: Opportunity and Unmet Need in the Cytomegalovirus Infections (Prophylactic)
Market, 2012
Figure 6: Opportunity and Unmet Need in the Cytomegalovirus Infections (Therapeutic) Market,
2012
Figure 7: Cytomegalovirus Infections Market, Clinical Pipeline by Mechanism of Action (%), 2012
Figure 8: Technology Trends Analytics Framework, 2012
Figure 9: Technology Trends Analytics Framework Unmet Need Gap Analysis, 2012
Figure 10: Cytomegalovirus Infections, Global, Clinical Trials by Country, 2012
Figure 11: Cytomegalovirus Infections Leading Companies Participating in Clinical Trials, 2012
Figure 12: Sales Forecasts ($m) for Cytomegalovirus Prophylactic Market in the Seven Major
Markets, 20112019
Figure 13: Sales Forecasts ($m) for Cytomegalovirus Therapeutic Market in the Seven Major
Markets, 20112019
Figure 14: Seven Major Market Sales for Cytomegalovirus Prophylactic Market by Region,
20112019
Figure 15: Seven Major Market Sales for Cytomegalovirus Therapeutic Market by Region,
20112019

Email ID- contact@jsbmarketresearch.com

Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Report Price:
Licence Type

Price

PDF

$ 5995

Site Licence

$ 11990

Enterprise Wide Licence

$ 17985

Related Reports:
Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market
Forecasts to 2018
Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018
Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Athletes Foot Therapeutics - Pipeline Assessment and Market Forecasts to 2019
HIV-Associated Diarrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Syphilis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Respiratory Syncytial Virus (RSV) Prophylactic - Pipeline Assessment and Market Forecasts to 2019
Vaginitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Clostridium difficile Infection (CDI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

You can order this report by calling on +91 - 998 7295 242 or mail us
your contact details at contact@jsbmarketresearch.com
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along
with providing in-depth analysis though reports, JSB market research also provides regular
updates of the market though newsletters. Our reports are a well-researched work of market
researchers with an extensive knowledge and a good level of market experience.

To know more on Cytomegalovirus (CMV) Infections - Pipeline Assessment and

Market Forecasts to 2019
http://www.jsbmarketresearch.com/healthcare-medical/r-cytomegaloviruscmv-infections-pipeline-assessment-and-market-forecasts-135247

Email ID- contact@jsbmarketresearch.com

Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/